A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Trial details
- Registry ID
- NCT05725018
- Drugs studied
- EB-101 Surgical application of RDEB wounds
TrialRedline tracks 1 clinical trial sponsored by Abeona Therapeutics, Inc: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsNCT05725018 | EB-101 Surgical application of RDEB wounds | Active not recruiting | 2025-09-30Estimated |
Names as written in the registry records.